rebel Financial rebel Financial
← All Posts
CRI

CRISPR THERAPEUTICS AG

June 05, 2026 • Author: Phil Ratcliff
Item Proposal Vote
1 Approval of the Swiss Management Report, the Consolidated Financial Statements and the Statutory Financial Statements of the Company for the year ended December 31, 2025. ✓ For
2 Approval of the Appropriation of Financial Results. ✓ For
3 Discharge of the Members of the Board of Directors and the Executive Committee. ✓ For
4 Re-election of the Members to the Board of Directors and the Chairman.
4.a Re-election of Samarth Kulkarni, Ph.D., as member and Chairman ✗ Against
4.b Re-election of Ali Behbahani, M.D. ✓ For
4.c Re-election of Maria Fardis, Ph.D. ✓ For
4.d Re-election of H. Edward Fleming, Jr., M.D. ✓ For
4.e Re-election of Simeon J. George, M.D. ✓ For
4.f Re-election of John T. Greene ✓ For
4.g Re-election of Katherine A. High, M.D. ✓ For
4.h Re-election of Sandesh Mahatme, LL.M. ✓ For
4.i Re-election of Briggs W. Morrison, M.D. ✓ For
4.j Re-election of Christian Rommel, Ph.D. ✓ For
4.k Re-election of Douglas A. Treco, Ph.D. ✓ For
5 Re-election of the Members of the Compensation Committee.
5.a Re-election of Ali Behbahani, M.D. ✓ For
5.b Re-election of H. Edward Fleming, Jr., M.D. ✓ For
5.c Re-election of John T. Greene ✓ For
5.d Re-election of Briggs W. Morrison, M.D. ✓ For
6 Approval of the Compensation for the Board of Directors and the Executive Committee and Non-Binding Advisory Vote on the 2025 Compensation Report.
6.a Binding vote on maximum non-performance-related compensation for members of the Board of Directors from the 2026 Annual General Meeting to the 2027 annual general meeting of shareholders. ✗ Against
6.b Binding vote on maximum equity for members of the Board of Directors from the 2026 Annual General Meeting to the 2027 annual general meeting of shareholders. ✗ Against
6.c Binding vote on maximum non-performance-related compensation for members of the Executive Committee from July 1, 2026 to June 30, 2027. ✗ Against
6.d Binding vote on maximum variable compensation for members of the Executive Committee for the current year ending December 31, 2026. ✗ Against
6.e Binding vote on maximum equity for members of the Executive Committee from the 2026 Annual General Meeting to the 2027 annual general meeting of shareholders. ✗ Against
6.f Non-binding advisory vote on the 2025 Compensation Report. ✓ For
7 Non-Binding Advisory Vote on the Compensation Paid to the Company’s Named Executive Officers under U.S. Securities Law Requirements. ✓ For
8 Approval of an Increase to the Company’s Capital Band. ✗ Against
9 Approval of an Increase to the Conditional Share Capital for the Conversion of Bonds and Similar Debt Instruments. ✓ For
10 Approval of the CRISPR Therapeutics AG 2026 Stock Option and Incentive Plan. ✓ For
11 Re-election of the Independent Voting Rights Representative. ✓ For
12 Re-election of the Auditors. ✓ For
13 Transact any Other Business that may Properly Come Before the 2026 Annual General Meeting or any Adjournment or Postponement thereof. ✓ For
Attachments
📄
CRSP_PROXY_STATEMENT.pdf 1.8 MB
📄
CRSP_ANNUAL_REPORT_2025.pdf 2.3 MB
This article was written for information purposes only and its content should not be construed by any consumer and/or prospective client as rebel Financial's solicitation to affect, or attempt to affect transactions in securities, or the rendering of personalized investment advice for compensation. No client or prospective client should assume that any such discussion serves as the receipt of, or a substitute for, personalized advice from rebel Financial, or from any other investment professional. See our disclosures page for more information.